Associated Genetic Biomarkers
RASA1 is altered in 0.18% of all cancers with colon adenocarcinoma, prostate adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in RASA1 are RASA1 Loss (0.12%) and RASA1 Amplification (0.01%) .
RASA1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains RASA1 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with RASA1 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is RASA1 Mutation .
Jsi-1187 is the most frequent therapy in trials with RASA1 as an inclusion criteria .
Significance of RASA1 in Diseases
Malignant Solid Tumor +
RASA1 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RASA1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) .
Non-Small Cell Lung Carcinoma +
RASA1 is altered in 0.16% of non-small cell lung carcinoma patients .
RASA1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RASA1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.